Sionna Therapeutics, Inc. $SION Shares Sold by Atlas Venture Life Science Advisors LLC

Atlas Venture Life Science Advisors LLC lowered its stake in Sionna Therapeutics, Inc. (NASDAQ:SION) by 2.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,615,527 shares of the company’s stock after selling 78,493 shares during the quarter. Sionna Therapeutics comprises about 14.1% of Atlas Venture Life Science Advisors LLC’s portfolio, making the stock its 4th biggest holding. Atlas Venture Life Science Advisors LLC owned about 8.10% of Sionna Therapeutics worth $106,333,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets boosted its stake in shares of Sionna Therapeutics by 35.2% in the third quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company’s stock valued at $70,000 after purchasing an additional 619 shares during the period. Legal & General Group Plc raised its position in Sionna Therapeutics by 436.7% in the 3rd quarter. Legal & General Group Plc now owns 7,374 shares of the company’s stock valued at $217,000 after purchasing an additional 6,000 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in Sionna Therapeutics in the third quarter valued at approximately $30,000. Intech Investment Management LLC purchased a new position in Sionna Therapeutics in the third quarter worth approximately $220,000. Finally, TD Asset Management Inc increased its holdings in Sionna Therapeutics by 74.3% in the third quarter. TD Asset Management Inc now owns 87,082 shares of the company’s stock valued at $2,561,000 after buying an additional 37,116 shares during the last quarter.

Sionna Therapeutics Stock Performance

Sionna Therapeutics stock opened at $37.32 on Friday. The company has a 50-day simple moving average of $38.53 and a 200-day simple moving average of $35.90. The firm has a market capitalization of $1.68 billion and a P/E ratio of -19.14. Sionna Therapeutics, Inc. has a one year low of $7.26 and a one year high of $45.00.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings results on Monday, March 2nd. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.15.

Wall Street Analyst Weigh In

SION has been the topic of several research analyst reports. UBS Group reissued a “buy” rating on shares of Sionna Therapeutics in a research report on Monday, March 2nd. Guggenheim upped their price objective on Sionna Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Wall Street Zen upgraded Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Citizens Jmp initiated coverage on shares of Sionna Therapeutics in a research note on Tuesday, February 24th. They issued a “market outperform” rating and a $63.00 target price for the company. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $50.57.

Insider Buying and Selling

In related news, Director Peter A. Thompson sold 29,063 shares of the firm’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $44.58, for a total transaction of $1,295,628.54. Following the completion of the sale, the director directly owned 3,530,702 shares in the company, valued at approximately $157,398,695.16. This trade represents a 0.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Tpg Gp A, Llc sold 250,000 shares of the stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $40.00, for a total value of $10,000,000.00. Following the completion of the transaction, the insider owned 6,494,962 shares of the company’s stock, valued at $259,798,480. This trade represents a 3.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 382,368 shares of company stock worth $15,898,607 in the last ninety days. 3.90% of the stock is currently owned by corporate insiders.

Sionna Therapeutics Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.